Salix Pharma (SLXP) Reports Q4 EPS of $2.61
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq climbs to record after softer jobs data cools rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Wells Fargo names 13 stocks as overweight tactical ideas
Salix Pharma (SLXP) Discloses SEC Probe into Possible Securities Law Violations
March 2, 2015 4:57 PM ESTSalix Pharma (NASDAQ: SLXP) disclosed the following in its 10-K filed after markets closed Monday:
The SEC is conducting an investigation into possible securities law violations, which may adversely affect our financial condition, results of operations and the price of our common... More
